Atea Pharmaceuticals Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
55
- Stock Symbol
-
AVIR
- Share Price
-
$4.12
- (As of Monday Closing)
Atea Pharmaceuticals General Information
Description
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Contact Information
Website
www.ateapharma.comCorporate Office
- 225 Franklin Street
- Suite 2100
- Boston, MA 02110
- United States
Corporate Office
- 225 Franklin Street
- Suite 2100
- Boston, MA 02110
- United States
Atea Pharmaceuticals Stock Performance
As of 16-Nov-2026, Atea Pharmaceuticals’s stock price is $4.12. Its current market cap is $331M with 80.3M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.12 | $4.30 | $2.92 - $6.45 | $331M | 80.3M | 281K | -$1.95 |
Atea Pharmaceuticals Financials Summary
As of 30-Sep-2026, Atea Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 198,825 | (49,351) | (198,027) | (338,063) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (171,638) | (180,471) | (192,534) | (163,746) |
| Net Income | (155,402) | (158,349) | (168,385) | (135,956) |
| Total Assets | 200,706 | 315,218 | 464,668 | 594,968 |
| Total Debt | 213 | 843 | 1,642 | 2,402 |
Atea Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Atea Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Atea Pharmaceuticals Comparisons
Industry
Financing
Details
Atea Pharmaceuticals Competitors (16)
One of Atea Pharmaceuticals’s 16 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| CytoAgents | Venture Capital-Backed | Pittsburgh, PA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Vir Biotechnology | Formerly VC-backed | San Francisco, CA | ||||
| Codagenix | Venture Capital-Backed | Farmingdale, NY |
Atea Pharmaceuticals Patents
Atea Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026161597-A1 | Advantageous fixed-dose combination treatment for hcv infection | Pending | 22-Jan-2025 | ||
| EP-4812173-A1 | Compositions and use thereof in treating hepatitis e infections with beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides | Pending | 10-Jan-2025 | ||
| WO-2026151964-A1 | Compositions and use thereof in treating hepatitis e infections with beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides | Pending | 10-Jan-2025 | ||
| WO-2026132293-A1 | Diaryl hydantoin compounds and uses thereof | Pending | 18-Dec-2024 | ||
| AU-2023276582-A1 | Dosage regimens for treatment of dengue infection | Pending | 26-May-2022 | A61K31/7076 |
Atea Pharmaceuticals Signals
Atea Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Atea Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.5 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Atea Pharmaceuticals FAQs
-
When was Atea Pharmaceuticals founded?
Atea Pharmaceuticals was founded in 2012.
-
Where is Atea Pharmaceuticals headquartered?
Atea Pharmaceuticals is headquartered in Boston, MA.
-
What is the size of Atea Pharmaceuticals?
Atea Pharmaceuticals has 55 total employees.
-
What industry is Atea Pharmaceuticals in?
Atea Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Atea Pharmaceuticals a private or public company?
Atea Pharmaceuticals is a Public company.
-
What is Atea Pharmaceuticals’s stock symbol?
The ticker symbol for Atea Pharmaceuticals is AVIR.
-
What is the current stock price of Atea Pharmaceuticals?
As of 16-Nov-2026 the stock price of Atea Pharmaceuticals is $4.12.
-
What is the current market cap of Atea Pharmaceuticals?
The current market capitalization of Atea Pharmaceuticals is $331M.
-
Who are Atea Pharmaceuticals’s competitors?
Inovio Pharmaceuticals, CytoAgents, Gilead, Vir Biotechnology, and Codagenix are some of the 16 competitors of Atea Pharmaceuticals.
-
What is Atea Pharmaceuticals’s annual earnings per share (EPS)?
Atea Pharmaceuticals’s EPS for 12 months was -$1.95.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process